Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al

Affiliations

• ¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
• ² Department of Biostatistics, Kyoto University School of Public Health, Kyoto, Japan.
• ³ Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
• ⁴ Department of Gastroenterology, National Center for Global Health and Medicine Center Hospital, Tokyo, Japan.
• ⁵ Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
• ⁶ Department of Hepatology, Osaka City University Hospital, Osaka, Japan.
• ⁷ Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
• ⁸ Department of Hepatobiliary and Pancreatic Surgery, Osaka National Hospital, Osaka, Japan.
• ⁹ Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
• ¹⁰ Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
• ¹¹ Department of Gastroenterology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
• ¹² Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, Japan.
• ¹³ Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
• ¹⁴ Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
• ¹⁵ Clinical Research Center, Shikoku Cancer Center, Matsuyama, Japan.
• ¹⁶ Department of Medical Oncology, Kyorin University, Tokyo, Japan.
• ¹⁷ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.